Inbrija Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628754 ACORDA Highly efficient delivery of a large therapeutic mass aerosol
Jun, 2020

(4 years ago)

US6921528 ACORDA Highly efficient delivery of a large therapeutic mass aerosol
Jun, 2020

(4 years ago)

US6514482 ACORDA Pulmonary delivery in treating disorders of the central nervous system
Sep, 2020

(3 years ago)

US6613308 ACORDA Pulmonary delivery in treating disorders of the central nervous system
Sep, 2020

(3 years ago)

US6979437 ACORDA Pulmonary delivery in treating disorders of the central nervous system
Sep, 2020

(3 years ago)

US7146978 ACORDA Inhalation device and method
Apr, 2021

(3 years ago)

US6858199 ACORDA High efficient delivery of a large therapeutic mass aerosol
Nov, 2021

(2 years ago)

US7556798 ACORDA Highly efficient delivery of a large therapeutic mass aerosol
Nov, 2021

(2 years ago)

US7384649 ACORDA Particulate compositions for pulmonary delivery
Nov, 2022

(1 year, 7 months ago)

US8586093 ACORDA Pulmonary delivery for levodopa
Mar, 2023

(1 year, 3 months ago)

US8404276 ACORDA Pulmonary delivery for levodopa
Mar, 2023

(1 year, 3 months ago)

US9155699 ACORDA Pulmonary delivery for levodopa
Mar, 2023

(1 year, 3 months ago)

US7182961 ACORDA Particulate compositions for pulmonary delivery
Feb, 2024

(4 months ago)

USRE43711 ACORDA Pulmonary delivery for levodopa
Feb, 2029

(4 years from now)

US8685442 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)

US8945612 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)

US8545878 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)

US9393210 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)



Inbrija is a drug owned by Acorda Therapeutics Inc. It is used for managing off episodes in Parkinson's disease patients treated with carbidopa/levodopa through the inhalation of levodopa powder particles. Inbrija uses Levodopa as an active ingredient. Inbrija was launched by Acorda in 2018. It is is available in powder form for inhalation use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 16, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 21, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step; Intermitt...

Dosage: POWDER

More Information on Dosage

INBRIJA family patents

Family Patents